Electronic Cigarettes: Their Constituents and Potential Links to Asthma

  • Phillip W. Clapp
  • Ilona JaspersEmail author
Allergies and the Environment (M Hernandez, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Allergies and the Environment


Purpose of Review

Vaping is gaining popularity in the USA, particularly among teens and young adults. While e-cigs are commonly represented as safer alternatives to tobacco cigarettes, little is known regarding the health effects of their short- or long-term use, especially in individuals with pre-existing respiratory diseases such as asthma. Flavored e-cig liquids (e-liquids) and e-cig aerosols contain airway irritants and toxicants that have been implicated in the pathogenesis and worsening of lung diseases. In this review, we will summarize existing data on potential health effects of components present in e-cig aerosols, such as propylene glycol, vegetable glycerin, nicotine, and flavorings, and discuss their relevance in the context of asthma.

Recent Findings

Recent survey data indicate that adolescents with asthma had a higher prevalence of current e-cig use (12.4%) compared to their non-asthmatics peers (10.2%) and conveyed positive beliefs about tobacco products, especially e-cigs. Similarly, a study conducted among high school students from Ontario, Canada, indicated a greater likelihood of e-cig use in asthmatics as compared to their non-asthmatic peers. Availability of different flavorings is often cited as the main reason among youth/adolescents for trying e-cigs or switching from cigarettes to e-cigs. Occupational inhalation of some common food-safe flavoring agents is reported to cause occupational asthma and worsen asthmatic symptoms. Moreover, workplace inhalation exposures to the flavoring agent diacetyl have caused irreversible obstructive airway disease in healthy workers. Additionally, recent studies report that thermal decomposition of propylene glycol (PG) and vegetable glycerin (VG), the base constituents of e-liquids, produces reactive carbonyls, including acrolein, formaldehyde, and acetaldehyde, which have known respiratory toxicities. Furthermore, recent nicotine studies in rodents reveal that prenatal nicotine exposures lead to epigenetic reprogramming in the offspring, abnormal lung development, and multigenerational transmission of asthmatic-like symptoms.


Comparisons of the toxicity and health effects of e-cigs and conventional cigarettes often focus on toxicants known to be present in cigarette smoke (CS) (i.e., formaldehyde, nitrosamines, etc.), as well as smoking-associated clinical endpoints, such as cancer, bronchitis, and chronic obstructive pulmonary disease (COPD). However, this approach disregards potential toxicity of components unique to flavored e-cigs, such as PG, VG, and the many different flavoring chemicals, which likely induce respiratory effects not usually observed in cigarette smokers.


E-cigarette and asthma E-liquid and asthma Asthma E-cigarette flavorings E-cigarette and inflammation Allergy 


Funding Information

This work was supported by the National Institutes of Health (NIH) grants T32-ES-007126 and P50-HL-120100. Research reported in this publication was in part supported by the NIH and the Food and Drug Administration Center for Tobacco Products. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Food and Drug Administration.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Organization WH. WHO global report on mortality attributable to tobacco. 2012.Google Scholar
  2. 2.
    Courtney R. The health consequences of smoking—50 years of progress: a report of the surgeon general, 2014 US Department of Health and Human Services Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 20141081 pp. Online (grey literature): http://www/. surgeongeneral. gov/library/reports/50-years-of-progress. Drug Alcohol Rev. 2015;34(6):694–5.CrossRefGoogle Scholar
  3. 3.
    Garrett BE, Dube S, Trosclair A, Caraballo R, Pechacek T. Cigarette smoking-United States, 1965–2008. MMWR Surveill Summ. 2011;60:109–13.Google Scholar
  4. 4.
    Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, et al. Youth risk behavior surveillance—United States, 2011. Morb Mortal Wkly Rep Surveill Summ. 2012;61(4):1–162.Google Scholar
  5. 5.
    Hopkins DP, Razi S, Leeks KD, Priya Kalra G, Chattopadhyay SK, Soler RE, et al. Smokefree policies to reduce tobacco use: a systematic review. Am J Prev Med. 2010;38(2 Suppl):S275–89. Scholar
  6. 6.
    Siegel M, Albers AB, Cheng DM, Hamilton WL, Biener L. Local restaurant smoking regulations and the adolescent smoking initiation process: results of a multilevel contextual analysis among Massachusetts youth. Arch Pediatr Adolesc Med. 2008;162(5):477–83. Scholar
  7. 7.
    Elders MJ, Perry CL, Eriksen MP, Giovino GA. The report of the Surgeon General: preventing tobacco use among young people. Am J Public Health. 1994;84(4):543–7.Google Scholar
  8. 8.
    Besaratinia A, Tommasi S. Electronic cigarettes: the road ahead. Prev Med. 2014;66:65–7. Scholar
  9. 9.
    Anand V, McGinty KL, O’Brien K, Guenthner G, Hahn E, Martin CA. E-cigarette use and beliefs among urban public high school students in North Carolina. J Adolesc Health. 2015;57(1):46–51.
  10. 10.
    Amrock SM, Zakhar J, Zhou S, Weitzman M. Perception of e-cigarette harm and its correlation with use among US adolescents. Nicotine Tob Res. 2015;17(3):330–6.
  11. 11.
    Geiss O, Bianchi I, Barrero-Moreno J. Correlation of volatile carbonyl yields emitted by e-cigarettes with the temperature of the heating coil and the perceived sensorial quality of the generated vapours. Int J Hyg Environ Health. 2016;219(3):268–77. Scholar
  12. 12.
    Kosmider L, Sobczak A, Fik M, Knysak J, Zaciera M, Kurek J, et al. Carbonyl compounds in electronic cigarette vapors: effects of nicotine solvent and battery output voltage. Nicotine Tob Res. 2014;16(10):1319–26. Scholar
  13. 13.
    • Sleiman M, Logue JM, Montesinos VN, Russell ML, Litter MI, Gundel LA, et al. Emissions from electronic cigarettes: key parameters affecting the release of harmful chemicals. Environ Sci Technol. 2016;50(17):9644–51. This study quantified potentially toxic compounds in e-cig aerosol emissions and identified key parameters affecting toxic compound generation, including heating coil configuration and applied voltage. PubMedCrossRefGoogle Scholar
  14. 14.
    Zezima K. Cigarettes without smoke or regulation. New York Times. 2009;1.Google Scholar
  15. 15.
    •• McNeill A, Brose L, Calder R, Hitchman S, Hajek P, McRobbie H. E-cigarettes: an evidence update. Public Health England. 2015;3. A government report by Public Health England (PHE), an agency of England’s Department of Health, which estimates that e-cigs are 95% less harmful to your health than normal cigarettes and supports the use of e-cigs as effective tobacco cessation and reduction aids. Google Scholar
  16. 16.
    • Zhu SH, Zhuang YL, Wong S, Cummins SE, Tedeschi GJ. E-cigarette use and associated changes in population smoking cessation: evidence from US current population surveys. BMJ. 2017;358:j3262. This study used survey data from the largest representative sample of e-cig users among the US population to show that that e-cig use is not only associated with a higher smoking cessation rate at the individual user level but also at the population level. PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    • Polosa R, Morjaria J, Caponnetto P, Caruso M, Strano S, Battaglia E, et al. Effect of smoking abstinence and reduction in asthmatic smokers switching to electronic cigarettes: evidence for harm reversal. Int J Environ Res Public Health. 2014;11(5):4965–77. A retrospective study which identifies improvements in asthma control, airway hyper-responsiveness, and pulmonary function in asthmatic smokers who quit or dramatically reduced their tobacco consumption by switching to e-cigs. PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Polosa R, Morjaria JB, Caponnetto P, Caruso M, Campagna D, Amaradio MD, et al. Persisting long term benefits of smoking abstinence and reduction in asthmatic smokers who have switched to electronic cigarettes. Discov Med. 2016;21(114):99–108.PubMedGoogle Scholar
  19. 19.
    Polosa R, Campagna D, Sands MF. Counseling patients with asthma and allergy about electronic cigarettes: an evidence-based approach. Ann Allergy Asthma Immunol. 2016;116(2):106–11. Scholar
  20. 20.
    •• Fedele DA, Barnett TE, Dekevich D, Gibson-Young LM, Martinasek M, Jagger MA. Prevalence of and beliefs about electronic cigarettes and hookah among high school students with asthma. Ann Epidemiol. 2016;26(12):865–9. This study used 2014 Florida Youth Tobacco Survey data ( n = 32,921) to assess current cigarette, hookah, and e-cig use among high school students with and without asthma. Adolescents with asthma had a higher prevalence of current hookah and e-cig use, reported positive beliefs about tobacco products, and were more likely to live with individuals who used cigarettes, hookah, and e-cig compared with their peers. PubMedCrossRefGoogle Scholar
  21. 21.
    •• Choi K, Bernat D. E-cigarette use among Florida youth with and without asthma. Am J Prev Med. 2016;51(4):446–53. A study which used the 2012 Florida Youth Tobacco Survey data ( n = 36,085) to assess the prevalence of e-cig use among asthmatic youth and examine the associations between e-cig use, susceptibility to cigarette smoking, and asthma attack. The authors conclude that e-cig use is more common among asthmatic youth and is associated with increased susceptibility to cigarette smoking. PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    •• Larsen K, GEJ F, Boak A, Hamilton HA, Mann RE, Irving HM, et al. Looking beyond cigarettes: are Ontario adolescents with asthma less likely to smoke e-cigarettes, marijuana, waterpipes or tobacco cigarettes? Respir Med. 2016;120:10–5. This study used the 2013 Ontario Student Drug Use and Health Survey data ( n = 6,159 high school students) to determine whether asthmatic students in Ontario smoke cigarettes, waterpipes, marijuana, or e-cig more or less than those without asthma. Students with asthma have higher odds of using e-cigs but not cigarettes, waterpipes, or marijuana, when compared to their non-asthmatic peers. PubMedCrossRefGoogle Scholar
  23. 23.
    •• Cho JH, Paik SY. Association between electronic cigarette use and asthma among high school students in South Korea. PLoS One. 2016;11(3):e0151022. This cross-sectional study investigated the association between e-cig use and asthma in 35,904 high school students. The authors report that e-cig users have an increased association with asthma and are more likely to have had days absent from school due to severe asthma symptoms. PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    •• Boulay ME, Henry C, Bosse Y, Boulet LP, Morissette MC. Acute effects of nicotine-free and flavour-free electronic cigarette use on lung functions in healthy and asthmatic individuals. Respir Res. 2017;18(1):33. A crossover, placebo-controlled study investigating the effects of a 1-h acute vaping session of nicotine- and flavor-free e-liquid on the pulmonary functions and respiratory mechanics of healthy and asthmatic individuals. Acute exposure to propylene glycol and glycerin aerosol in a controlled environment does not significantly impact pulmonary function or symptoms in both healthy and asthmatic subjects. PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Ferrari M, Zanasi A, Nardi E, Morselli Labate AM, Ceriana P, Balestrino A, et al. Short-term effects of a nicotine-free e-cigarette compared to a traditional cigarette in smokers and non-smokers. BMC Pulm Med. 2015;15:120. Scholar
  26. 26.
    Flouris AD, Chorti MS, Poulianiti KP, Jamurtas AZ, Kostikas K, Tzatzarakis MN, et al. Acute impact of active and passive electronic cigarette smoking on serum cotinine and lung function. Inhal Toxicol. 2013;25(2):91–101. Scholar
  27. 27.
    Varughese S, Teschke K, Brauer M, Chow Y, van Netten C, Kennedy SM. Effects of theatrical smokes and fogs on respiratory health in the entertainment industry. Am J Ind Med. 2005;47(5):411–8. Scholar
  28. 28.
    • Wang P, Chen W, Liao J, Matsuo T, Ito K, Fowles J, et al. A device-independent evaluation of carbonyl emissions from heated electronic cigarette solvents. PLoS One. 2017;12(1):e0169811. Quantitation of toxic volatile carbonyl compounds produced when vaping propylene glycol and glycerin under precisely controlled temperatures in the absence of nicotine and flavor additives. PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Yao Y, Liang W, Zhu L, Duan Y, Jin Y, He L. Relationship between the concentration of formaldehyde in the air and asthma in children: a meta-analysis. Int J Clin Exp Med. 2015;8(6):8358–62.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Tillett T. Formaldehyde exposure among children: a potential building block of asthma. Environ Health Perspect. 2010;118(3):A 131. Scholar
  31. 31.
    Golden R, Holm S. Indoor air quality and asthma: has unrecognized exposure to acrolein confounded results of previous studies? Dose Response. 2017;15(1):1559325817691159. Scholar
  32. 32.
    Prieto L, Gutierrez V, Cervera A, Linana J. Airway obstruction induced by inhaled acetaldehyde in asthma: repeatability relationship to adenosine 5′-monophosphate responsiveness. J Investig Allergol Clin Immunol. 2002;12(2):91–8.PubMedGoogle Scholar
  33. 33.
    Yildiz D. Nicotine, its metabolism and an overview of its biological effects. Toxicon. 2004;43(6):619–32. Scholar
  34. 34.
    Benowitz NL, Hukkanen J, Jacob III P. Nicotine chemistry, metabolism, kinetics and biomarkers. Nicotine psychopharmacology. Springer; 2009. p. 29–60.Google Scholar
  35. 35.
    D’alessandro A, Boeckelmann I, Hammwhöner M, Goette A. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. Eur J Prev Cardiol. 2012;19(3):297–305.PubMedCrossRefGoogle Scholar
  36. 36.
    Kershbaum A, Bellet S, Dickstein ER, Feinbergl J. Effect of cigarette smoking and nicotine on serum free fatty acids based on a study in the human subject and the experimental animal. Circ Res. 1961;9:631–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Kershbaum A, Osada H, Pappajohn DJ, Bellet S. Effect of nicotine on the mobilization of free fatty acids from adipose tissue in vitro. Experientia. 1969;25(2):128.PubMedCrossRefGoogle Scholar
  38. 38.
    Carlson LA, Orö L. The effect of nicotinic acid on the plasma free fatty acids demonstration of a metabolic type of sympathicolysis. J Intern Med. 1962;172(6):641–5.Google Scholar
  39. 39.
    Omvik P. How smoking affects blood pressure. Blood Press. 1996;5(2):71–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Wright S, Zhong J, Zheng H, Larrick J. Nicotine inhibition of apoptosis suggests a role in tumor promotion. FASEB J. 1993;7(11):1045–51.PubMedGoogle Scholar
  41. 41.
    Walker LM, Preston MR, Magnay JL, Thomas PB, El Haj AJ. Nicotinic regulation of c-fos and osteopontin expression in human-derived osteoblast-like cells and human trabecular bone organ culture. Bone. 2001;28(6):603–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Nisell M, Nomikos GG, Chergui K, Grillner P, Svensson TH. Chronic nicotine enhances basal and nicotine-induced Fos immunoreactivity preferentially in the medial prefrontal cortex of the rat. Neuropsychopharmacology. 1997;17(3):151–61. Scholar
  43. 43.
    Whitley D, Goldberg SP, Jordan WD. Heat shock proteins: a review of the molecular chaperones. J Vasc Surg. 1999;29(4):748–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Doolittle DJ, Winegar R, Lee CK, Caldwell WS, Hayes AW, Donald deBethizy J. The genotoxic potential of nicotine and its major metabolites. Mutat Res Genet Toxicol. 1995;344(3–4):95–102.CrossRefGoogle Scholar
  45. 45.
    Rehan VK, Liu J, Naeem E, Tian J, Sakurai R, Kwong K, et al. Perinatal nicotine exposure induces asthma in second generation offspring. BMC Med. 2012;10:129. Scholar
  46. 46.
    Liu J, Sakurai R, Rehan VK. PPAR-gamma agonist rosiglitazone reverses perinatal nicotine exposure-induced asthma in rat offspring. Am J Physiol Lung Cell Mol Physiol. 2015;308(8):L788–96. Scholar
  47. 47.
    Rehan VK, Liu J, Sakurai R, Torday JS. Perinatal nicotine-induced transgenerational asthma. Am J Physiol Lung Cell Mol Physiol. 2013;305(7):L501–7. Scholar
  48. 48.
    Benowitz NL, Henningfield JE. Reducing the nicotine content to make cigarettes less addictive. Tob Control. 2013;22(suppl 1):i14–i7.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Galle-Treger L, Suzuki Y, Patel N, Sankaranarayanan I, Aron JL, Maazi H, et al. Nicotinic acetylcholine receptor agonist attenuates ILC2-dependent airway hyperreactivity. Nat Commun. 2016;7:13202. Scholar
  50. 50.
    Mabley J, Gordon S, Pacher P. Nicotine exerts an anti-inflammatory effect in a murine model of acute lung injury. Inflammation. 2011;34(4):231–7. Scholar
  51. 51.
    Kalra R, Singh SP, Pena-Philippides JC, Langley RJ, Razani-Boroujerdi S, Sopori ML. Immunosuppressive and anti-inflammatory effects of nicotine administered by patch in an animal model. Clin Diagn Lab Immunol. 2004;11(3):563–8. Scholar
  52. 52.
    Kalra R, Singh SP, Kracko D, Matta SG, Sharp BM, Sopori ML. Chronic self-administration of nicotine in rats impairs T cell responsiveness. J Pharmacol Exp Ther. 2002;302(3):935–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Sopori ML, Kozak W, Savage SM, Geng Y, Soszynski D, Kluger MJ, et al. Effect of nicotine on the immune system: possible regulation of immune responses by central and peripheral mechanisms. Psychoneuroendocrinology. 1998;23(2):189–204.PubMedCrossRefGoogle Scholar
  54. 54.
    Sopori ML, Kozak W, Savage SM, Geng Y, Kluger MJ. Nicotine-induced modulation of T cell function. Implications for inflammation and infection. Adv Exp Med Biol. 1998;437:279–89.PubMedCrossRefGoogle Scholar
  55. 55.
    Sopori ML, Kozak W. Immunomodulatory effects of cigarette smoke. J Neuroimmunol. 1998;83(1–2):148–56.PubMedCrossRefGoogle Scholar
  56. 56.
    Bencherif M, Lippiello PM, Lucas R, Marrero MB. Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. Cell Mol Life Sci. 2011;68(6):931–49. Scholar
  57. 57.
    Mishra NC, Rir-Sima-Ah J, Langley RJ, Singh SP, Pena-Philippides JC, Koga T, et al. Nicotine primarily suppresses lung Th2 but not goblet cell and muscle cell responses to allergens. J Immunol. 2008;180(11):7655–63.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Chen EY, Sun A, Chen CS, Mintz AJ, Chin WC. Nicotine alters mucin rheological properties. Am J Physiol Lung Cell Mol Physiol. 2014;307(2):L149–57. Scholar
  59. 59.
    Gundavarapu S, Wilder JA, Mishra NC, Rir-Sima-Ah J, Langley RJ, Singh SP, et al. Role of nicotinic receptors and acetylcholine in mucous cell metaplasia, hyperplasia, and airway mucus formation in vitro and in vivo. J Allergy Clin Immunol. 2012;130(3):770–780 e11. Scholar
  60. 60.
    Razani-Boroujerdi S, Singh SP, Knall C, Hahn FF, Pena-Philippides JC, Kalra R, et al. Chronic nicotine inhibits inflammation and promotes influenza infection. Cell Immunol. 2004;230(1):1–9. Scholar
  61. 61.
    Zhu SH, Sun JY, Bonnevie E, Cummins SE, Gamst A, Yin L, et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control. 2014;23(Suppl 3):iii3–9. Scholar
  62. 62.
    Harrell MB, Weaver SR, Loukas A, Creamer M, Marti CN, Jackson CD, et al. Flavored e-cigarette use: characterizing youth, young adult, and adult users. Prev Med Rep. 2017;5:33–40. Scholar
  63. 63.
    Pepper JK, Ribisl KM, Brewer NT. Adolescents’ interest in trying flavoured e-cigarettes. Tob Control. 2016;25(Suppl 2):ii62–i6. Scholar
  64. 64.
    Cobb CO, Hendricks PS, Eissenberg T. Electronic cigarettes and nicotine dependence: evolving products, evolving problems. BMC Med. 2015;13:119. Scholar
  65. 65.
    Dai H, Hao J. Flavored electronic cigarette use and smoking among youth. Pediatrics. 2016;138:e20162513.PubMedCrossRefGoogle Scholar
  66. 66.
    Zhong J, Cao S, Gong W, Fei F, Wang M. Electronic cigarettes use and intention to cigarette smoking among never-smoking adolescents and young adults: a meta-analysis. Int J Environ Res Public Health. 2016;13(5):pii: E465.
  67. 67.
    Padon AA, Maloney EK, Cappella JN. Youth-targeted e-cigarette marketing in the US. Tob Regul Sci. 2017;3(1):95–101.PubMedCrossRefGoogle Scholar
  68. 68.
    Behar RZ, Luo W, Lin SC, Wang Y, Valle J, Pankow JF, et al. Distribution, quantification and toxicity of cinnamaldehyde in electronic cigarette refill fluids and aerosols. Tob Control. 2016;25(Suppl 2):ii94–ii102. Scholar
  69. 69.
    Clapp PW, Pawlak EA, Lackey JT, Keating JE, Reeber SL, Glish GL, et al. Flavored e-cigarette liquids and cinnamaldehyde impair respiratory innate immune cell function. Am J Physiol Lung Cell Mol Physiol. 2017;
  70. 70.
    Kreiss K, Gomaa A, Kullman G, Fedan K, Simoes EJ, Enright PL. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N Engl J Med. 2002;347(5):330–8. Scholar
  71. 71.
    van Rooy FG, Rooyackers JM, Prokop M, Houba R, Smit LA, Heederik DJ. Bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings. Am J Respir Crit Care Med. 2007;176(5):498–504. Scholar
  72. 72.
    Barrington-Trimis JL, Samet JM, McConnell R. Flavorings in electronic cigarettes: an unrecognized respiratory health hazard? JAMA. 2014;312(23):2493–4. Scholar
  73. 73.
    •• Farsalinos KE, Kistler KA, Gillman G, Voudris V. Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins. Nicotine Tob Res. 2015;17(2):168–74. This study found that diacetyl and acetyl propionyl, known respiratory toxicants, were present in a large proportion of sweet-flavored e-cig liquids. The authors conclude that the use of many of the products evaluated would result in exposures that exceed NIOSH-defined safety levels. PubMedCrossRefGoogle Scholar
  74. 74.
    Alert N. Preventing Lung Disease in Workers Who Use or Make Flavorings. NIOSH Publication No. 2004-110. 2003.Google Scholar
  75. 75.
    Lopez-Saez MP, Carrillo P, Huertas AJ, Fernandez-Nieto M, Lopez JD. Occupational asthma and dermatitis induced by eugenol in a cleaner. J Investig Allergol Clin Immunol. 2015;25(1):64–5.PubMedGoogle Scholar
  76. 76.
    Quirce S, Fernandez-Nieto M, del Pozo V, Sastre B, Sastre J. Occupational asthma and rhinitis caused by eugenol in a hairdresser. Allergy. 2008;63(1):137–8. Scholar
  77. 77.
    Kern AB. Contact dermatitis from cinnamon. Arch Dermatol. 1960;81:599–600.PubMedCrossRefGoogle Scholar
  78. 78.
    Vandersall A, Katta R. Eyelid dermatitis as a manifestation of systemic contact dermatitis to cinnamon. Dermatitis. 2015;26(4):189. Scholar
  79. 79.
    Lauriola MM, De Bitonto A, Sena P. Allergic contact dermatitis due to cinnamon oil in galenic vaginal suppositories. Acta Derm Venereol. 2010;90(2):187–8. Scholar
  80. 80.
    Ackermann L, Aalto-Korte K, Jolanki R, Alanko K. Occupational allergic contact dermatitis from cinnamon including one case from airborne exposure. Contact Dermatitis. 2009;60(2):96–9. Scholar
  81. 81.
    Hartmann K, Hunzelmann N. Allergic contact dermatitis from cinnamon as an odour-neutralizing agent in shoe insoles. Contact Dermatitis. 2004;50(4):253–4. Scholar
  82. 82.
    Sanchez-Perez J, Garcia-Diez A. Occupational allergic contact dermatitis from eugenol, oil of cinnamon and oil of cloves in a physiotherapist. Contact Dermatitis. 1999;41(6):346–7.PubMedCrossRefGoogle Scholar
  83. 83.
    De Benito V, Alzaga R. Occupational allergic contact dermatitis from cassia (Chinese cinnamon) as a flavouring agent in coffee. Contact Dermatitis. 1999;40(3):165.PubMedGoogle Scholar
  84. 84.
    Uragoda CG. Asthma and other symptoms in cinnamon workers. Br J Ind Med. 1984;41(2):224–7.PubMedPubMedCentralGoogle Scholar
  85. 85.
    •• Kosmider L, Sobczak A, Prokopowicz A, Kurek J, Zaciera M, Knysak J, et al. Cherry-flavoured electronic cigarettes expose users to the inhalation irritant, benzaldehyde. Thorax. 2016;71(4):376–7. This study measured benzaldehyde, a known respiratory irritant, in aerosol generated from flavored e-cigs purchased online. Benzaldehyde was detected in 108 out of 145 products. PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Laham S, Broxup B, Robinet M, Potvin M, Schrader K. Subacute inhalation toxicity of benzaldehyde in the Sprague-Dawley rat. Am Ind Hyg Assoc J. 1991;52(12):503–10. Scholar
  87. 87.
    Andersen A. Final report on the safety assessment of benzaldehyde. Int J Toxicol. 2006;25(Suppl 1):11–27. Scholar
  88. 88.
    Leikauf GD. 12 formaldehyde and other aldehydes. Environmental toxicants: human exposures and their health effects. 2000:409.Google Scholar
  89. 89.
    Leikauf GD. Mechanisms of aldehyde-induced bronchial reactivity: role of airway epithelium. Res Rep Health Eff Inst. 1992;49:1–35.Google Scholar
  90. 90.
    Leikauf GD. Hazardous air pollutants and asthma. Environ Health Perspect. 2002;110(Suppl 4):505–26.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Annesi-Maesano I, Hulin M, Lavaud F, Raherison C, Kopferschmitt C, de Blay F, et al. Poor air quality in classrooms related to asthma and rhinitis in primary schoolchildren of the French 6 Cities Study. Thorax. 2012;67(8):682–8. Scholar
  92. 92.
    Jang TY, Park CS, Kim KS, Heo MJ, Kim YH. Benzaldehyde suppresses murine allergic asthma and rhinitis. Int Immunopharmacol. 2014;22(2):444–50. Scholar
  93. 93.
    Spurlock BW, Dailey TM. Shortness of (fresh) breath--toothpaste-induced bronchospasm. N Engl J Med. 1990;323(26):1845–6.PubMedGoogle Scholar
  94. 94.
    Subiza J, Subiza JL, Valdivieso R, Escribano PM, Garcia R, Jerez M, et al. Toothpaste flavor-induced asthma. J Allergy Clin Immunol. 1992;90(6 Pt 1):1004–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Paiva M, Piedade S, Gaspar A. Toothpaste-induced anaphylaxis caused by mint (Mentha) allergy. Allergy. 2010;65(9):1201–2. Scholar
  96. 96.
    Plevkova J, Kollarik M, Poliacek I, Brozmanova M, Surdenikova L, Tatar M, et al. The role of trigeminal nasal TRPM8-expressing afferent neurons in the antitussive effects of menthol. J Appl Physiol (1985). 2013;115(2):268–74. Scholar
  97. 97.
    Willis DN, Liu B, Ha MA, Jordt SE, Morris JB. Menthol attenuates respiratory irritation responses to multiple cigarette smoke irritants. FASEB J. 2011;25(12):4434–44. Scholar
  98. 98.
    •• Tierney PA, Karpinski CD, Brown JE, Luo W, Pankow JF. Flavour chemicals in electronic cigarette fluids. Tob Control. 2016;25(e1):e10–5. This study quantified flavoring chemicals in 30 popular e-cig liquids. Many of the e-liquids contained aldehyde flavoring agents that made up 1 to 4% of the total e-liquid volume. The authors conclude that concentrations of some flavor chemicals in e-cigs are sufficiently high for inhalation exposure by vaping to be of toxicological concern. PubMedCrossRefGoogle Scholar
  99. 99.
    Berridge MJ, Lipp P, Bootman MD. Signal transduction. The calcium entry pas de deux. Science. 2000;287(5458):1604–5.PubMedCrossRefGoogle Scholar
  100. 100.
    Montell C. The TRP superfamily of cation channels. Sci STKE. 2005;2005(272):re3. Scholar
  101. 101.
    Geppetti P, Materazzi S, Nicoletti P. The transient receptor potential vanilloid 1: role in airway inflammation and disease. Eur J Pharmacol. 2006;533(1–3):207–14. Scholar
  102. 102.
    Jia Y, Lee LY. Role of TRPV receptors in respiratory diseases. Biochim Biophys Acta. 2007;1772(8):915–27. Scholar
  103. 103.
    Takemura M, Quarcoo D, Niimi A, Dinh QT, Geppetti P, Fischer A, et al. Is TRPV1 a useful target in respiratory diseases? Pulm Pharmacol Ther. 2008;21(6):833–9. Scholar
  104. 104.
    Lee LY, Gu Q. Role of TRPV1 in inflammation-induced airway hypersensitivity. Curr Opin Pharmacol. 2009;9(3):243–9. Scholar
  105. 105.
    Lee LY, Ni D, Hayes D Jr, Lin RL. TRPV1 as a cough sensor and its temperature-sensitive properties. Pulm Pharmacol Ther. 2011;24(3):280–5. Scholar
  106. 106.
    Cantero-Recasens G, Gonzalez JR, Fandos C, Duran-Tauleria E, Smit LA, Kauffmann F, et al. Loss of function of transient receptor potential vanilloid 1 (TRPV1) genetic variant is associated with lower risk of active childhood asthma. J Biol Chem. 2010;285(36):27532–5. Scholar
  107. 107.
    Chen CL, Li H, Xing XH, Guan HS, Zhang JH, Zhao JW. Effect of TRPV1 gene mutation on bronchial asthma in children before and after treatment. Allergy Asthma Proc. 2015;36(2):e29–36. Scholar
  108. 108.
    Rehman R, Bhat YA, Panda L, Mabalirajan U. TRPV1 inhibition attenuates IL-13 mediated asthma features in mice by reducing airway epithelial injury. Int Immunopharmacol. 2013;15(3):597–605. Scholar
  109. 109.
    Rogerio AP, Andrade EL, Calixto JB. C-fibers, but not the transient potential receptor vanilloid 1 (TRPV1), play a role in experimental allergic airway inflammation. Eur J Pharmacol. 2011;662(1–3):55–62. Scholar
  110. 110.
    Yocum GT, Chen J, Choi CH, Townsend EA, Zhang Y, Xu D, et al. Role of transient receptor potential vanilloid 1 in the modulation of airway smooth muscle tone and calcium handling. Am J Physiol Lung Cell Mol Physiol. 2017;312(6):L812–L21. Scholar
  111. 111.
    Brooks SM. Irritant-induced chronic cough: irritant-induced TRPpathy. Lung. 2008;186(Suppl 1):S88–93. Scholar
  112. 112.
    Facchinetti F, Patacchini R. The rising role of TRPA1 in asthma. Open Drug Discov J. 2010;2(1):71–80.CrossRefGoogle Scholar
  113. 113.
    • Yang H, Li S. Transient receptor potential ankyrin 1 (TRPA1) channel and neurogenic inflammation in pathogenesis of asthma. Med Sci Monit. 2016;22:2917–23. This review discusses how activation of TRPA1 expressed in C-fiber nociceptors promotes neurogenic inflammation in asthma. PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Bessac BF, Jordt SE. Breathtaking TRP channels: TRPA1 and TRPV1 in airway chemosensation and reflex control. Physiology (Bethesda). 2008;23:360–70. Scholar
  115. 115.
    Symanowicz PT, Gianutsos G, Morris JB. Lack of role for the vanilloid receptor in response to several inspired irritant air pollutants in the C57Bl/6J mouse. Neurosci Lett. 2004;362(2):150–3. Scholar
  116. 116.
    Hinman A, Chuang HH, Bautista DM, Julius D. TRP channel activation by reversible covalent modification. Proc Natl Acad Sci U S A. 2006;103(51):19564–8. Scholar
  117. 117.
    Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, et al. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007;445(7127):541–5. Scholar
  118. 118.
    Andersson DA, Gentry C, Moss S, Bevan S. Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci. 2008;28(10):2485–94. Scholar
  119. 119.
    Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell. 2006;124(6):1269–82. Scholar
  120. 120.
    Bessac BF, Sivula M, von Hehn CA, Escalera J, Cohn L, Jordt SE. TRPA1 is a major oxidant sensor in murine airway sensory neurons. J Clin Invest. 2008;118(5):1899–910. Scholar
  121. 121.
    Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267–84. Scholar
  122. 122.
    Caceres AI, Brackmann M, Elia MD, Bessac BF, del Camino D, D’Amours M, et al. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. Proc Natl Acad Sci U S A. 2009;106(22):9099–104. Scholar
  123. 123.
    Premkumar LS. Transient receptor potential channels as targets for phytochemicals. ACS Chem Neurosci. 2014;5(11):1117–30.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    • Wu SW, Fowler DK, Shaffer FJ, Lindberg JEM, Peters JH. Ethyl vanillin activates TRPA1. J Pharmacol Exp Ther. 2017;362(3):368–77. This study provides evidence that ethyl vanillin, a common e-cig flavoring agent, is a potent activator of TRPA1. PubMedCrossRefGoogle Scholar
  125. 125.
    Xu H, Delling M, Jun JC, Clapham DE. Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci. 2006;9(5):628–35. Scholar
  126. 126.
    Inoue M, Fujita T, Goto M, Kumamoto E. Presynaptic enhancement by eugenol of spontaneous excitatory transmission in rat spinal substantia gelatinosa neurons is mediated by transient receptor potential A1 channels. Neuroscience. 2012;210:403–15. Scholar
  127. 127.
    Chung G, Im ST, Kim YH, Jung SJ, Rhyu MR, Oh SB. Activation of transient receptor potential ankyrin 1 by eugenol. Neuroscience. 2014;261:153–60. Scholar
  128. 128.
    Kaimoto T, Hatakeyama Y, Takahashi K, Imagawa T, Tominaga M, Ohta T. Involvement of transient receptor potential A1 channel in algesic and analgesic actions of the organic compound limonene. Eur J Pain. 2016;20(7):1155–65. Scholar
  129. 129.
    Silverman RA, Hasegawa K, Egan DJ, Stiffler KA, Sullivan AF, Camargo CA. Multicenter study of cigarette smoking among adults with asthma exacerbations in the emergency department, 2011–2012. Respir Med. 2017;125:89–91.PubMedCrossRefGoogle Scholar
  130. 130.
    Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J. 2004;24(5):822–33.

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Curriculum in Toxicology, School of MedicineUniversity of North CarolinaChapel HillUSA
  2. 2.Center for Environmental Medicine, Asthma, and Lung Biology, School of MedicineUniversity of North CarolinaChapel HillUSA
  3. 3.Department of PediatricsUniversity of North CarolinaChapel HillUSA

Personalised recommendations